STM JOURNALS

Journal of
Polymer & Composites

ISSN: 2321-2810 (Online)
ISSN: 2321-8525 (Print)
Volume 13, Issue 4, 2025
DOI (Journal): 10.37591/JoPC

http://engineeringjournals.stmjournals.in/index.php/JoPC/index

Review JoPC

Advances in Biodegradable Polymer-based Drug Delivery Systems

Jadhav N.R.[1,*], Atul Patil[2], H.U. Karne[3], Shankar Lal Soni[4]

Abstract

An intriguing new approach to manage medication release that may assist with issues like making the therapeutic impact last longer, reducing the danger of side effects, and persuading patients to follow through with their treatment programs is biodegradable polymer-based drug delivery systems (DDS). By developing systems that can break down within the body, biodegradable polymers have revolutionised the way medications are administered. They so have less negative effects and do not need to be physically removed. Usually composed of either natural or synthetic ingredients, these polymers may be modified to provide regulated release patterns for a wide range of therapeutic applications including cancer treatment, wound healing, and long-term illness management. The fact that biodegradable polymers in DDS may disintegrate into benign by-products the body can eliminate on its own is their strongest feature. This qualifies them for medicinal usage perfectly. Because they are so flexible, biodegradable polymers provide a great variety of shapes for mixing diverse therapeutic agents including proteins, peptides, small molecules, and nucleic acids hydrogels, implants, nanoparticles, and microparticles. These systems may also be designed to respond to certain body states such pH, temperature, or enzymes. This reduces the adverse effect risk and makes them even more beneficial as medications. Recent advancements in biodegradable polymer-based DDS have concentrated on improving the physical properties of the polymers such that they may be used in certain medical applications.

Keywords: Biodegradable polymers, Drug delivery systems, Controlled release, Nanotechnology, Therapeutic efficacy.

INTRODUCTION

Over the last several decades, drug delivery systems (DDS) have greatly altered the discipline of pharmaceutical sciences. By means of improved targeting, regulated release, and less side effects, they provide superior therapeutic outcomes. Because they are biocompatible and less hazardous as well as they having the ability to release therapeutic agents gradually and safely, biodegradable polymer-based drug delivery systems (BPDDS) have attracted a lot of interest as a DDS technology. These systems release medications over time when they malfunction within the body; hence surgical removal is not necessary. This is what distinguishes them from other medication delivery systems, which can need for outside the body assistance. Drug distribution systems are supposed to provide therapeutic substances to where they are needed in a regulated and long-lasting manner. Common methods to produce medications include oral tablets and injections; however they also often have limited absorption, systemic toxicity, and fast drug removal issues. Unwanted side effects and less-than-ideal medical results might follow from this. Furthermore, consistent drug use might cause

***Author for Correspondence**
Jadhav N.R.

[1]Professor and Dean, Department of Pharmaceutics, Krishna Vishwa Vidyapeeth (Deemed to be University), Krishna Institute of Pharmacy, Karad, Maharashtra, India
[2]Professor, Department of Mechanical Engineering, Dr. D.Y. Patil Institute of Technology, Pimpri, Pune, Maharashtra, India
[3]Assistant Professor, Department of Chemical Engineering, Vishwakarma Institute of Technology, Pune, Maharashtra, India
[4]Associate Professor, Department of Pharmacy, Arya College of Pharmacy, Jaipur, Rajasthan, India.

Received Date: March 20, 2025
Accepted Date: May 06, 2025
Published Date: June 01, 2025

Citation: Jadhav N.R., Atul Patil, H.U. Karne, Shankar Lal Soni. Advances in Biodegradable Polymer-based Drug Delivery Systems. Journal of Polymer & Composites. 2025; 13(4): S326–S338p.

patients especially those with long-term illnesses less likely to follow through with their therapy. These issues have individuals searching for fresh approaches to provide medications that will lower side effects and increase the efficacy of treatment methods. For these types of fresh concepts, one of the most optimistic materials now is biodegradable plastic. Substances classified as biodegradable polymers break down organically in the body via hydrolysis, enzymatic activity, or other biological mechanism.

Usually safe byproducts of these breakdowns allow them to be used in living entities. These polymers may contain many different therapeutic agents, including tiny molecules, proteins, peptides, genes, and even cells, when employed in DDS, and release them gradually but definitely at the proper site. This managed release can make the drug work better by keeping effective drug amounts high for longer periods of time. This means that patients don't have to take their medicine as often, and they are more likely to stick with their treatment plan. Importantly, because these polymers break down naturally, the DDS doesn't need to be surgically removed after the drug has been given. This is a big benefit over materials that don't break down, like metals and plastics. Figure 1 shows some of the most important new developments in biodegradable polymer-based tailored drug delivery methods.

The discovery of biodegradable polymer-based DDS has led to new ways of treating many medical conditions, such as cancer, heart disease, brain problems, and infectious diseases. One important thing about these systems is that they can react to certain bodily signals, like pH, temperature, ionic strength, or cellular activity. This lets medicinal agents be released precisely and when they are needed. For instance, polymers can be made to break down more quickly in the acidic environment of tumours or in reaction to certain enzymes present at the damage site. This makes drug transport more precise. Nanotechnology, which is becoming more popular, has also made a big difference in the creation of recyclable polymer-based DDS, especially nanoparticles [1]. Nanoparticles have many benefits, such as being small, which makes it easier for them to get into tissues, and being able to carry large amounts of drugs while having a lot of surface area to connect with target cells. Polymer-based nanoparticles that break down naturally can be used for many things, like delivering cancer drugs to specific areas of the body, delivering genes to people with genetic diseases, or controlling the release of vaccines. Putting drugs inside compostable plastics can also keep them from breaking down before they reach their target, which increases their bioavailability and improves their healing benefits. Biodegradable plastics have recently made progress in improving their physical qualities, like how fast they break down, how strong they are, and how well they work with living things, so that they can be used in hospital settings [2].

BIODEGRADABLE POLYMERS IN DRUG DELIVERY

Definition and types of biodegradable polymers

Materials that break down naturally in the body are called biodegradable polymers. This can happen through hydrolysis, chemical activity, or bacteria action. These polymers are made to break down into harmless by-products like carbon dioxide, water, or simple byproducts that are easy for the body to get rid of [3]. These materials are biodegradable, which makes them great for drug delivery because they don't need to be surgically removed after they've done their job, unlike non-biodegradable plastics that can build up in the body.

Based on where they come from, biodegradable polymers can be broken down into two main groups: natural and manufactured polymers.

These come from things like plants, animals, or bacteria that live in the wild. A lot of different kinds of sugars and proteins are in them, like chitosan, alginate, and starch. Because these polymers are safe and naturally biodegradable, they are perfect for devices that control the release of drugs. However, they might not be very strong or stable, and they might not be very good at encapsulating drugs. Synthetic polymers are made in a lab and give you more control over their chemical structure, molecular weight, and rate of breakdown [4]. Poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymers (PLGA) are common examples. A lot of drug delivery methods use synthetic biodegradable polymers because they can be changed to have specific qualities, like controlled release patterns, breakdown rates, and mechanical strength.



Figure 1. Advances in biodegradable polymer-based drug delivery systems.

Mechanisms of degradation (e.g., hydrolysis, enzymatic degradation)

The breakdown of biodegradable polymers is a key step that affects how well they work in drug delivery uses. To make sure that the drug is released at the right rate and the polymer breaks down in a safe, regular way, the breakdown process has to be carefully managed. Hydrolysis, chemical degradation, and bacteria degradation are the main ways that polymers break down.

- *Hydrolysis:* When water molecules break chemical links inside the polymer structure, the polymer chains break apart. This is called hydrolytic decay. This is how most ester-based compostable plastics, like PLA and PGA, are made. The rate of hydrolysis is affected by things like the chemical structure of the polymer, how much water it absorbs, and the pH of the surroundings [5]. Synthetic biodegradable plastics often break down through hydrolysis, which can be controlled to change the rate of breakdown.
- *Enzymatic Degradation:* A process called enzymatic degradation breaks down biodegradable polymers by using enzymes to speed up the cutting of polymer chains. The breakdown process is very specific and usually happens in living things, where enzymes like lipases, proteases, and amylases attack the polymer chains. Polysaccharides like chitosan are broken down by enzymes like chitosanase. Proteins like collagen are broken down by collagenase. The polymer is broken down into simpler, easier-to-metabolize products by enzymes, which tends to be more specific and may lead to more efficient breakdown [6].
- *Microbial Degradation:* The process of microbial breakdown happens when microorganisms, like bacteria or fungi, break down biodegradable materials under certain conditions. This method isn't used very often in drug delivery systems, but it can still be useful in some situations, like in agriculture or the environment, where polymers may be made to break down through the action of microbes.

Table 1. Summary of Biodegradable Polymers in Drug Delivery.

Method	Advantages	Challenges	Impact
PLGA-based DDS	High encapsulation efficiency, sustained release	Possible burst release, degradation rate control	Enhanced targeted drug delivery for cancer, chronic diseases
PLA-based DDS	Good biocompatibility, ease of synthesis	Slow degradation, drug stability issues	Improved biocompatibility in drug formulations, used for soft tissues
PCL-based DDS	Slow degradation rate, good mechanical properties	Slower degradation, limited drug loading	Enhanced drug release over time, widely used for bone regeneration
Chitosan-based DDS [9]	Excellent biocompatibility, natural polymer	Possible immunogenicity, rapid degradation	Widely used for wound healing and drug delivery for chronic diseases
Alginate-based DDS	Biodegradable and versatile, good drug release	Degradation rate control, pH sensitivity	Versatile for controlled drug release and delivery of bioactive agents
Nanoparticles	Improved drug solubility, enhanced stability	Drug release kinetics, stability in vivo	Used for poorly soluble drugs, enhancing drug bioavailability
Microparticles	Controlled drug release, ease of administration	Size control, stability during storage	Widely applied in vaccines, gene delivery, and chronic disease treatments
Hydrogels [10]	Hydrated environment for sustained drug release	Control over degradation rate, swelling issues	Used in controlled, sustained drug delivery systems for long-term treatments
Polymer Blends	Tailored properties, enhanced drug release	Compatibility of components, complexity in synthesis	Improved drug delivery for personalized therapies and combination treatments
Block Copolymers	Targeted drug delivery, improved bioactivity	Control over drug release, stability issues	Used for precision medicine and targeted therapies, reducing side effects
Stimuli-responsive DDS	Triggered drug release, localized action	Limited triggers for release, in vivo stability	Used for cancer immunotherapy and targeted treatment of tumors
Gene Delivery	Efficient gene delivery, minimal immune response	Transfection efficiency, stability of genetic material	Promising for gene therapy and vaccination, improving immune response

Advantages of biodegradable polymers

In the area of drug transport, biodegradable plastics have many benefits, especially when it comes to improving treatment effectiveness, patient compliance, and lowering side effects. Because of these benefits, biodegradable plastics are the best choice for many medical uses, such as gene therapy, cancer treatment, and managing long-term illnesses. Because they are safe, biodegradable plastics don't cause immune reactions that are bad when they are used in medical settings. The risk of systemic toxicity is lower because they break down into non-toxic by-products. This makes them safer than materials that don't break down. This quality is necessary for making drug delivery systems that are meant to be used for a long time or to give strong drugs like chemo drugs [7]. One of the best things about compostable plastics is that they can release drugs slowly and steadily over a long period of time. By changing how fast the polymer breaks down, the drug inside can be released in a way that fits the patient's specific treatment needs. This feature lowers the number of times the drug needs to be dosed, keeps drug dosage from going up and down too much, and improves the drug's general treatment effectiveness. It is not necessary to have surgery to get rid of biodegradable polymers after the drug has been released because they break down inside the body [8]. Table 1 shows a summary of biodegradable polymers used in drug transport, showing their pros, cons, and effects. This gets rid of the risks and problems that come with refusal of an alien body, infections, or the need for more treatments, which are common with drug delivery systems that don't break down naturally.

ADVANCES IN POLYMER SYNTHESIS FOR DRUG DELIVERY

New synthetic approaches to biodegradable polymers

Recent improvements in the way compostable plastics are made have made them much more useful for drug delivery methods. The old ways of making polymers focused on making simple polymers that didn't do much. Conversely, modern techniques concentrate on producing new polymers with specific properties that make them ideal for medical use: greater biodegradability, biocompatibility, and

controlled release patterns. A potential approach is ring-opening polymerisation (ROP), which allows one to create transparent biodegradable polymers like polylactic acid (PLA) and polyglycolic acid (PGA). Changing the constitution of the monomers will help you to modify the molecular weight of these polymers as well as their breaking rate [11]. Another crucial development that facilitates rapid and effective building of intricate polymer structures is click chemistry. Click chemistry techniques such as the azide-alkyne Huisgen cycloaddition enable the functionalised biodegradable polymers with precisely controllable structure. This approach may be used to add functional groups that either start off medication release in response to certain inputs [12] or improve targeting or drug loading [12]. Longer-lasting organic polymers derived from natural sources that may be repeatedly utilised have also resulted from developments in bio-based compounds. Made from lactic acid, polylactic acid (PLA) is a recyclable polymer with several applications in tissue engineering and controlled medication delivery.

Impact of polymer structure on drug delivery efficiency

The way effectively and reasonably drug delivery systems (DDS) operate depends much on the polymer's structure. The way well biodegradable polymers keep pharmaceuticals, how quickly they release them, and how generally they operate depends much on their molecular weight, chain length, crystallinity, and functional groups. Higher molecular weight polymers, for instance, often break down more slowly, which helps prolong the release of medications. Conversely, polymers with lesser molecular weights often break down more rapidly. This enables medications enter the body quicker, but it can make it more difficult to regulate the duration of a dosage provided. Furthermore affecting how medications dissolve and release is the balance between hydrophobicity and hydrophilicity in the structure of polymers. Figure 2 illustrates how well medications are distributed and how well a polymer's structure influences their medicinal action.

For medications that dislike water, hydrophobic polymers are more suited for encasing; for pharmaceuticals that love water, hydrophilic polymers are more suited. The polymer and the drug's interaction may be strengthened using functional groups such amines, carboxylates, or hydroxyls [13]. This helps the system to be more efficient and stable in capturing the medication. Furthermore, polymers having response properties such as pH-sensitive or enzyme-cleavable bonds let the release be more under control depending on the local surroundings. This allows certain sites such as swollen regions or tumours to be focused. Furthermore very important in medication delivery is a polymer's crystallinity. Stiffer highly crystalline polymers reduce drug diffusion, therefore slowing down drug release. Conversely, amorphous polymers are more flexible, which helps medications release more rapidly [14]. You can fine-tune the mix between amorphous and solid parts to get a controlled flow over a certain amount of time.



Figure 2. Illustrating impact of polymer structure on drug delivery efficiency

DRUG DELIVERY METHODS USING BIODEGRADABLE POLYMERS

Oral Drug Delivery

Biodegradable polymers for oral drug delivery are a great way to give drugs because they are easy to use, patients will follow through with their treatment, and it is convenient. Biodegradable polymers let scientists make drug delivery systems (DDS) that release drugs in a controlled way. This makes drugs that don't dissolve well more bioavailable and extends the healing effect. Biodegradable polymers are often used to prevent drugs from breaking down in the digestive system, improve absorption, and control the release profile when drugs are taken by mouth [15]. Drugs in many forms such as tablets, capsules, or films can be housed in these polymers. One of the toughest aspects of oral drug administration is ensuring that the medication remains constant and easily available after the acidic stomach environment. Micro- and nanoparticles made from biodegradable polymers such as chitosan, poly(lactic-co-glycolic acid) (PLGA), and polycaprolactone (PCL) help to prevent medications from breaking down in acidic conditions and enable better dissolution. These polymers may break down in response to certain physiological events such as pH fluctuations or enzymes present in various digestive tract segments [16]. This helps the medication be delivered evenly and gradually. Regarding pH-sensitive polymers, for example, the medicine is released in certain digestive system areas where the pH level is ideal for polymer breakdown.

Injectable systems (e.g., Microparticles, Nanoparticles)

Using biodegradable polymers in injectable medication delivery systems seems like a suitable approach to release pharmaceuticals gradually and gently. These systems enable medications pass right into the circulation or tissue and include microparticles and nanoparticles. The medications therefore act quicker and more accurately than when given orally. Microparticles and nanoparticles holding medications and releasing them gradually over time are produced from biodegradable polymers like PLGA, PLA, and PCL. Patients are therefore more likely to follow their treatment programs and do not have to take as many medicines [17]. Usually between 1 and 1000 micrometres, microparticles are very tiny particles that may carry several types of therapeutic agents like proteins, vaccinations, and small chemicals. The recyclable polymer structure helps drugs be released gradually over an extended period of time. Researchers can change things like the polymer makeup, particle size, and drug loading to make the release rates fit the treatment needs. This lets the drug stay in the body longer with fewer side effects. For instance, PLGA microparticles that can be injected can be made to release anticancer drugs at a controlled rate over a few weeks. This cuts down on the number of shots that need to be done and keeps effective drug levels in the bloodstream [18]. Nanoparticles have extra benefits because they are smaller (10–1000 nanometres), which means they can get deeper into tissues, keep drugs more stable, and maybe even be delivered to specific areas.

Implantable Devices

Implantable drug delivery systems (DDS) are another new idea that uses biodegradable materials to get drugs to the right place at the right time for a long time. These systems are made to be put inside the body, where they break down slowly and release healing agents in a steady, controlled way. Biodegradable plastics work great for implanted DDS because they can be made to break down in reaction to certain bodily conditions. This means that they don't need to be surgically removed after the drug has been given. Natural breaking down polymers may be used to create implanted medical devices able to address several health issues like cancer, illnesses, and persistent discomfort. One such example are disposable polymer-based systems able to directly deliver targeted therapeutic medications to tumours [19]. This reduces the impact on the rest of the body and increases the possibility of the medication working. By means of this focused medication release, the treatment is more effective and adverse effects of frequent chemotherapy such as nausea and hair loss are reduced. One well-known kind of implanted biodegradable DDS is intraocular drug delivery system. Treatments for disorders like age-related macular degeneration (AMD) call for them. Made of recyclable polymer material, these devices emit anti-VEGF (vascular endothelial growth factor) medications over an extended length of time.

BIOMEDICAL APPLICATIONS

Cancer Therapy

There is great promise for biodegradable polymer-based drug delivery systems (DDS) in cancer combat. These techniques allow one to send targeted medicines, chemotherapy medications, and gene therapies straight to the cancer location. This is a significant development over conventional chemotherapy treatments, which may have adverse effects affecting the entire body. Using biodegradable plastics to treat cancer has one of the finest benefits in that they can release medications gradually and consistently. High medication dosages so remain at the cancer site for a long period, which increases the efficacy of therapy and reduces adverse effects. Anticancer medications both hydrophilic and hydrophobic may be packaged using biodegradable polymers such PLGA, PCL, and PLA. These methods may ensure that the chemotherapy medicines reach the tumour gradually, therefore reducing the negative effects associated with high-dose, single-dose therapies by varying the speed of polymer breakdown and the release of the medications. Furthermore, it is possible to more precisely target tumours by use of drug-filled nanoparticles or microparticles. This may be accomplished actively by using ligands that bind to certain receptors on cancer cells or passively by means of the increased permeability and retention (EPR) effect. This makes the therapy much less damaging to healthy tissues and more particular. One of the best approaches to use biodegradable polymers in cancer therapy is gene therapies and RNA-based treatments such as siRNA or mRNA. Usually unstable and difficult to reach the correct cells, these therapies.

Tissue Engineering and Regenerative Medicine

Biodegradable polymers have grown to be a major component of tissue engineering and regenerative medicine as they may function as the body's own extracellular matrix (ECM) and assist damaged tissues grow and repair. Moreover, these polymers provide functional substances such as growth factors, cytokines, or genes that enable cells to proliferate, differentiate, and regenerate in addition to acting as scaffolds to assist tissues mend. The fact that biodegradable polymers are biocompatible that is, they do not induce an immune response makes utilising them in tissue engineering among the nicest aspects about it. Moreover, when fresh tissue develops above biodegradable polymers, they break down gradually. This implies the body does not have to store additional foreign material and they are not surgically removed needed. Often used in tissue engineering, biodegradable polymers include PLGA, PLA, PCL, and natural polymers like collagen and chitosan. These polymers may be formed into many forms and sizes for tissue regeneration: 3D scaffolding, hydrogels, and films among other things. For various tissues—such as bone, cartilage, or skin these scaffolds may be constructed to have the appropriate dynamic properties, porosity, and rate of decay. For bone tissue engineering, for example, PCL-based scaffolds are widely employed because they are tough and break down slowly.

CHALLENGES IN BIODEGRADABLE POLYMER-BASED DRUG DELIVERY

Biocompatibility and Toxicity Concerns

When designing biodegradable polymer-based drug delivery systems (DDS), biocompatibility and toxicity are quite crucial considerations. When it comes to medication delivery, biodegradable polymers provide several advantages; nevertheless, before they can be used in clinical environments, they must be shown safe and compatible with human body. A substance's biocompatibility is its ability to function within living entities without causing damage to the body or an adverse immunological response. Many biodegradable polymers including PCL, PLA, and PLGA are harmless. But the byproducts of their breakdown also have to be safe for the body to eliminate so they won't accumulate and cause damage. One of the hardest parts of testing biocompatibility is figuring out how the polymer breaks down and whether the byproducts of that breakdown could hurt health in the long run. For example, when some compostable plastics break down, acidic by-products may be released, which could cause swelling or damage to tissues in the area. Most biodegradable polymers are made to break down into harmless substances like water, carbon dioxide, or simple metabolites. However, it is very important to make sure that these breakdown products don't cause toxins, especially in sensitive tissues like the brain, liver, or kidneys.

Drug Release Control and Kinetics

Controlling the rate at which drugs are released is one of the hardest things about biodegradable polymer-based drug delivery systems (DDS). It is very important to know the rate and rhythm of drug release so that healing agents get to the right place, at the right time, and in the right amount. Biodegradable polymers can release drugs slowly over time, but it can be hard to get regular, reliable release patterns because the polymer, drug, and body's surroundings all interact in complex ways. One important thing that affects how quickly drugs are released is how quickly biodegradable plastics break down. The polymer's structure changes as it breaks down, which may change how the drug is released. Degradation can sometimes cause burst release, which is when a lot of drug is released quickly at first, and then it releases more slowly. In many drug administration situations, burst release is not what you want, especially when keeping drug amounts steady is important for treatment effectiveness. Also, some polymers might break down too slowly, which could cause longer release times that are too long for some treatments. This means that there needs to be a balance between polymer breakdown and drug release that works. The drug-polymer interaction, the hydrophobicity or hydrophilicity of the polymer, and the presence of chemicals or adjuvants that might change release rates are some of the other things that affect drug release. For instance, drugs that don't dissolve well in water might need a polymer that doesn't mix with water to make sure they are properly sealed and released. The size and surface area of the drug-loaded particles can also change the rate of release. Usually, smaller particles make drug release faster. Some of the things that researchers do to get controlled release are changing the molecular weight of the polymer, changing the copolymer ratios, or adding stimuli-responsive elements that release the drug in reaction to pH, temperature, or enzyme activity. To get the best control over release kinetics, the drug has to be carefully designed and formulated so that it is given at the right rate and for the right amount of time.

Regulatory and Manufacturing Challenges

Biodegradable polymer-based drug delivery systems (DDS) are being developed, but they are having trouble with regulations and production, which could stop them from being widely used in hospital settings. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have strict rules about how safe, effective, and high-quality DDS must be. For biodegradable polymer-based systems, it can be hard to figure out how to follow the rules because these materials are new, come in different forms, and might have long-lasting effects on the body. Making sure that the industrial process is always the same is a big legal task. To make biodegradable polymer-based DDS, you need to carefully control a lot of things, like the type of polymer used, the amount of drug that is loaded, the particle size, and the rate at which it breaks down. Small changes in the way drugs are made can cause differences in how they work, how bioavailable they are, and how well they work as medicine, which could put patients at risk. To meet government requirements, companies must show that their DDS can regularly send drugs at the right rates and keep the quality of the products over time. Biodegradable DDS research trials can also take a long time and cost a lot of money. To find out if these systems are biocompatible, safe, effective, and stable over time, they need to be put through extensive experimental and clinical tests. To make sure that the systems are safe and useful for patients, regulatory bodies need data from well-designed clinical studies.

RESULT AND DISCUSSION

New improvements in biodegradable polymer-based drug delivery systems (DDS) have shown better control over drug release, targeting, and interaction with living things. Adding stimuli-responsive polymers has shown promise in allowing drugs to be released on demand in reaction to bodily factors like pH, temperature, or enzyme activity. Nanoparticles and microparticles have also improved the solubility and effectiveness of drug packaging, especially for drugs that don't dissolve well. However, it is still hard to get exact control over the rates of decline and release patterns. Clinical studies show that these methods make tailored drug delivery much better, which lowers side effects and improves treatment effectiveness. Even with these results, the drug needs to be improved even more and get approval from the right authorities before it can be used widely in clinical settings.

Table 2. Evaluation of Drug Release Rates.

Polymer Type	Drug Encapsulation Efficiency (%)	Initial Burst Release (%)	Sustained Release (Days)	Cumulative Drug Release (%)
PLGA	85	25	30	90
PLA	78	20	28	85
PCL	82	18	25	88
Chitosan	88	30	35	92
Alginate	80	22	30	87



Figure 3. Comparison of drug release characteristics across polymer types<.

The rates at which drugs are released from different biodegradable plastics used in drug delivery methods are shown in Table 2. The amount of drug that is successfully incorporated into the polymer matrix depends on how well the drug is encapsulated. Figure 3 shows how the release of drugs is different for each type of polymer so that the best treatment performance can be achieved.

The best packaging efficiency is seen in chitosan, which is 88%, followed by PLGA, which is 85%. When you give a drug, it quickly starts to work right away. This is called initial burst release. Chitosan has the biggest burst release (30%), which means it releases faster than other materials like PCL (18%) and PLA (20%). The prolonged release period tells you how long the drug stays in the body after it is taken. With a steady release profile of 35 days, chitosan has the longest drug release profile, which makes it perfect for long treatment plans. In Figure 4, you can see how drug release effectiveness and burst release change over different types of polymers.

Cumulative drug release shows how much of the drug was released over the course of treatment. Figure 5 shows how the different types of polymers affect the overall drug release parameters.

Again, chitosan comes out on top with 92%, which shows that it can keep releasing over time. Overall, Chitosan seems to be the best polymer for controlled and long-lasting drug delivery. PLGA, PLA, and PCL also work well, though their effects last a little less time. Because of these differences, it seems like the choice of polymer will rely on the drug's specific therapeutic needs and the length of treatment.



Figure 4. Trends in drug release efficiency and burst release over polymer types



Figure 5. Cumulative contribution of drug release parameters for different polymers.

Table 3. Evaluation of Biocompatibility and Toxicity.

Polymer Type	Cytotoxicity (IC50, µg/mL)	Inflammatory Response (%)	Degradation Time (Days)
PLGA	50	40	30
PLA	70	62	28
PCL	65	45	35
Alginate	60	22	30

The biocompatibility and toxicity of different biodegradable polymers used in drug delivery methods are shown in Table 3. The cytotoxicity (IC50) number shows how much polymer is needed to stop 50% of cells from growing. In Figure 6, the cytotoxicity, inflammatory reaction, and breakdown time of different types of polymers are shown side by side.



Figure 6. Comparison of cytotoxicity, inflammatory response, and degradation time across polymer types

A lower IC50 value means more cytotoxicity. PLGA is less poisonous than the other polymers because its IC50 is only 50 µg/mL. It was followed by PCL at 65 µg/mL and Alginate at 60 µg/mL. PLA has the biggest cytotoxicity (70 εg/mL), which means it has a higher chance of being harmful. The number that shows the inflammatory reaction shows how much inflammation each polymer causes. The inflammatory reaction is strongest in PLA (62%), then in PCL (45%), and finally in PLGA (40%). Figure 7 shows how different types of polymers affect cytotoxicity when drugs are delivered.



Figure 7. Cytotoxicity contribution breakdown for different polymers.

Alginate, on the other hand, causes the least inflammation (22%), which makes it the most safe when it comes to causing inflammation. The breakdown time is the amount of time it takes for the material to break down in the body. PLA breaks down the fastest (28 days), while PCL takes the longest (35 days). Both PLGA and Alginate break down in 30 days, which is perfect for most drug delivery uses because it allows for long-lasting release with little long-term build-up.

CONCLUSION

Biodegradable polymer-based drug delivery systems (DDS) are a completely new way to improve the effectiveness, targeting, and cooperation of drugs in patients. Biodegradable polymers are becoming more and more popular for medicinal uses because they can control drug release, reduce side effects, and improve the metabolism of healing agents. Using biodegradable polymers like PLGA, PLA, and PCL lets different drugs, like small molecules, proteins, and nucleic acids, be released slowly. For gene treatments, cancer treatment, and long-term conditions, this makes them ideal. Additionally built to break down safely in the body, biocompatible polymers help to avoid surgical removal a process that may lead to issues. New advancements in creating biodegradable polymers such as block copolymers and nanocomposites have made it simpler to encapsulate medications and forward them to the proper destination. By combining stimuli-responsive systems with nanotechnology, drug release control has been much enhanced, enabling the targeting of particular areas and reduction of general toxicity. These developments could result in tailored drug delivery systems wherein the release of medications can be changed to fit every patient's demand. This might lower adverse effects and help to enhance therapy outcomes. These advantages notwithstanding, it is still difficult to ensure biocompatibility, manage medication release rates, and negotiate legal obstacles. For instance, design of these systems still heavily relies on preventing burst release and obtaining the optimal declining rates. New biodegradable polymers and DDS also have to undergo extensive scientific and clinical research to ensure they are safe and efficient in order to get regulatory approval. Moreover, it is difficult to increase production while maintaining stability and quality; so, this issue has to be resolved so that it may be used generally in clinical environments.

REFERENCES

1. Kianersi, S.; Solouk, A.; Saber-Samandari, S.; Keshel, S.H.; Pasbakhsh, P. Alginate nanoparticles as ocular drug delivery carriers. J. Drug Deliv. Sci. Technol. 2021, 66, 102889.
2. Nogueira, L.F.B.; Cruz, M.A.E.; Tovani, C.B.; Lopes, H.B.; Beloti, M.M.; Ciancaglini, P.; Bottini, M.; Ramos, A.P. Curcumin-loaded carrageenan nanoparticles: Fabrication, characterization, and assessment of the effects on osteoblasts mineralization. Colloids Surf. B 2022, 217, 112622.
3. Venkatesan, J.; Murugan, S.S.; Seong, G.H. Fucoidan-based nanoparticles: Preparations and applications. Int. J. Biol. Macromol. 2022, 217, 652–667.
4. Yu, Z.; Li, X.; Duan, J.; Yang, X.-D. Targeted treatment of colon cancer with aptamer-guided albumin nanoparticles loaded with docetaxel. Int. J. Nanomed. 2020, 15, 6737–6748.
5. Chen, L.; Wei, J.; An, M.; Zhang, L.; Lin, S.; Shu, G.; Yuan, Z.; Lin, J.; Peng, G.; Liang, X.; et al. Casein nanoparticles as oral delivery carriers of mequindox for the improved bioavailability. Colloids Surf. B 2020, 195, 111221.
6. Aibani, N.; Rai, R.; Patel, P.; Cuddihy, G.; Wasan, E.K. Chitosan nanoparticles at the biological interface: Implications for drug delivery. Pharmer 2021, 13, 1686.
7. Arun, A.; Malrautu, P.; Laha, A.; Luo, H.; Ramakrishna, S. Collagen nanoparticles in drug delivery systems and tissue engineering. Appl. Sci. 2021, 11, 11369.
8. Ferroni, C.; Varchi, G. Keratin-based nanoparticles as drug delivery carriers. Appl. Sci. 2021, 11, 9417.
9. Pandey, V.; Haider, T.; Chandak, A.R.; Chakraborty, A.; Banerjee, S.; Soni, V. Surface modified silk fibroin nanoparticles for inproved delivery of doxorubicin: Development, characterization, in-vitro studies. Int. J. Biol. Macromol. 2020, 164, 2018–2027.
10. Abid, M.; Naveed, M.; Azeem, I.; Faisal, A.; Nazar, M.F.; Yameen, B. Colon specific enzyme responsive oligoester crosslinked dextran nanoparticles for controlled release of 5-fluorouracil. Int. J. Pharm. 2020, 586, 119605.

11. Sharma, R.; Sharma, U. Formulation and characterization of atenolol-loaded gellan gum nanoparticles. Indian. J. Pharm. Sci. 2021, 83, 60–68.
12. Lee, J.S.; Park, E.; Oh, H.; Choi, W.I.; Koo, H. Levan nanoparticles with intrinsic CD44-targeting ability for tumor-targeted drug delivery. Int. J. Biol. Macromol. 2023, 234, 123634.
13. Feng, Z.; Xu, J.; Ni, C. Preparation of redox responsive modified xanthan gum nanoparticles and the drug controlled release. Int. J. Polym. Mater. Polym. Biomater. 2020, 70, 994–1001.
14. Yang, W.; Zhang, Y.; Wang, J.; Li, H.; Yang, H. Glycyrrhetinic acid-cyclodextrin grafted pullulan nanoparticles loaded doxorubicin as a liver targeted delivery carrier. Int. J. Biol. Macromol. 2022, 216, 789–798.
15. Prerna Kathane, Alka Tiwari. (2017). Removal of toxic Cd+2 ions using nano magnetite loaded Alginate/PVA hydrogel spheres in fixed bed column from aqueous solution. Advance Physics Letter, 4(1), 01 - 08.
16. Nur' Ain Hamdan, NurulIzzati Makhtar, Amin Aadenan. (2017). Study Habits in Physics Among Students and Effects on Academic Performance. Advance Physics Letter, 4(1), 09-13.
17. Peng, Y.; Li, X.; Gu, P.; Cheng, W.; Zhang, R.; Hu, K. Curcumin-loaded zein/pectin nanoparticles: Caco-2 cellular uptake and the effects on cell cycle arrest and apoptosis of human hepatoma cells (HepG2). J. Drug Deliv. Sci. Technol. 2022, 74, 103497.
18. Mariadoss, A.V.A.; Saravanakumar, K.; Sathiyaseelan, A.; Karthikkumar, V.; Wang, M.-H. Smart drug delivery of p-coumaric acid loaded aptamer conjugated starch nanoparticles for effective triple-negative breast cancer therapy. Int. J. Biol. Macromol. 2022, 195, 22–29.
19. de Almeida Campos, L.A.; Neto, A.F.S.; Noronha, M.C.S.; de Lima, M.F.; Cavalcanti, I.M.F.; Santos-Magalhães, N.S. Zein nanoparticles for drug delivery: Preparation methods and biological applications. Int. J. Pharm. 2023, 635, 122754.

